Atherosclerosis overview: Difference between revisions

Jump to navigation Jump to search
(Created page with "__NOTOC__ {{Atherosclerosis}} {{CMG}} ==Overview== '''Atherosclerosis''' is a disease affecting arterial blood vessels. It is a chronic inflammatory respon...")
 
m (Bot: Removing from Primary care)
 
(10 intermediate revisions by 3 users not shown)
Line 1: Line 1:
<div style="-webkit-user-select: none;">
{|class="infobox" style="position: fixed; top: 65%; right: 10px; margin: 0 0 0 0; border: 0; float: right;
|-
| {{#ev:youtube|https://https://www.youtube.com/watch?v=MjC1-odNY5k|350}}
|-
|}
__NOTOC__
__NOTOC__
{{Atherosclerosis}}
{{Atherosclerosis}}
Line 6: Line 12:
'''Atherosclerosis''' is a [[disease]] affecting [[artery|arterial]] [[blood vessel]]s. It is a chronic inflammatory response in the walls of arteries, in large part due to the deposition of [[lipoproteins]] (plasma proteins that carry cholesterol and [[triglycerides]]). It is commonly referred to as a "hardening" or "furring" of the arteries. It is caused by the formation of multiple [[atheroma|plaques]] within the [[arteries]].
'''Atherosclerosis''' is a [[disease]] affecting [[artery|arterial]] [[blood vessel]]s. It is a chronic inflammatory response in the walls of arteries, in large part due to the deposition of [[lipoproteins]] (plasma proteins that carry cholesterol and [[triglycerides]]). It is commonly referred to as a "hardening" or "furring" of the arteries. It is caused by the formation of multiple [[atheroma|plaques]] within the [[arteries]].


[[anatomical pathology|Pathologically]], the '''[[atheroma|atheromatous plaque]]''' is divided into three distinct components:
==Pathophysiology==
# The ''[[atheroma]]'' ("lump of porridge", from ''Athera'', porridge in Greek,) is the nodular accumulation of a soft, flaky, yellowish material at the center of large plaques, composed of [[macrophage]]s nearest the [[lumen (anatomy)|lumen]] of the artery.
Atherogenesis is the developmental process of atheromatous plaques. It is characterized by a remodeling of [[artery|arteries]] involving the concomitant accumulation of fatty substances called plaques. One recent theory suggests that for unknown reasons, [[leukocytes]] such as [[monocytes]] or [[basophils]] begin to attack the [[endothelium]] of the artery lumen in cardiac muscle. The ensuing [[inflammation]] leads to formation of atheromatous plaques in the arterial [[tunica intima]], a region of the vessel wall located between the [[endothelium]] and the [[tunica media]] and [[tunica adventitia]]. The bulk of these lesions are made of excess fat, [[collagen]], and [[elastin]]. Initially, as the plaques grow only [[intima-media thickness|wall thickening]] occurs without any narrowing, stenosis of the artery opening, called the lumen; [[stenosis]] is a late event which may never occur and is often the result of repeated plaque rupture and healing responses, not the just atherosclerosis process by itself.
# Underlying areas of [[cholesterol]] crystals.
# Calcification at the outer base of older/more advanced lesions.


The following terms are similar, yet distinct, in both spelling and meaning, and can be easily confused: arteriosclerosis, arteriolosclerosis and atherosclerosis.  '''Arteriosclerosis''' is a general term describing any hardening (and loss of elasticity) of medium or large arteries (in Greek, "Arterio" meaning artery and "sclerosis" meaning hardening), '''arteriolosclerosis''' is  atherosclerosis mainly affecting the [[arteriole]]s (small arteries), '''atherosclerosis''' is a hardening of an artery specifically due to an atheromatous plaque. Therefore, atherosclerosis is a form of arteriosclerosis.
==Diagnosis==
===History and Symptoms===


Atherosclerosis causes two main problems. First, the [[atheroma|atheromatous plaques]], though long compensated for by artery enlargement, see [[intima-media thickness|IMT]], eventually lead to plaque ruptures and ''stenosis'' (narrowing) of the artery and, therefore, an insufficient blood supply to the organ it feeds. Alternatively, if the compensating artery enlargement process is excessive, then a net [[aneurysm]] results.
According to United States data for the year 2004, for about 65% of men and 47% of women, the first [[symptom]] of atherosclerotic [[cardiovascular disease]] is [[myocardial infarction|heart attack]] or [[sudden cardiac death]] (death within one hour of onset of the symptom).


These complications are chronic, slowly progressing and cumulative.  Most commonly, soft plaque suddenly ''ruptures'' (see [[vulnerable plaque]]), causing the formation of a thrombus that will rapidly slow or stop blood flow, e.g. 5 minutes, leading to death of the tissues fed by the artery. This catastrophic event is called an ''[[infarction]]''. One of the most common recognized scenarios is called [[coronary thrombosis]] of a [[coronary artery]] causing [[myocardial infarction]] (a heart attack). Another common scenario in very advanced disease is ''[[claudication]]'' from insufficient blood supply to the legs, typically due to a combination of both stenosis and aneurysmal segments narrowed with [[thrombus|clots]]. Since atherosclerosis is a body wide process, similar events also occur in the arteries to the brain, intestines, kidneys, legs, etc.
===Laboratory Findings===
 
[[Cardiac stress test]]ing, traditionally the most commonly performed non-invasive testing method for blood flow limitations generally only detects [[lumen (anatomy)|lumen]] narrowing of ~75% or greater, although some physicians advocate that nuclear stress methods can detect as little as 50%.
 
==Treatment==
===Medical Therapy===
If atherosclerosis leads to symptoms, some symptoms such as [[angina pectoris]] can be treated. Non-pharmaceutical means are usually the first method of treatment, such as cessation of smoking and practicing regular exercise. If these methods do not work, medicines are usually the next step in treating cardiovascular diseases, and with improvements, have increasingly become the most effective method over the long term. However, medicines are criticized for their expense, patented control and occasional undesired effects.
 
===Future or Investigational Therapies===
Since about 2002, progress in understanding and developing techniques for modulating immune system function so as to significantly suppress the action of macrophages to drive atherosclerotic plaque progression are being developed with considerable success in reducing plaque development in both mice and rabbits. Plans for human trials, hoped for by about 2008, are in progress. Generally these techniques are termed immunomodulation of atherosclerosis.


==References==
==References==
Line 22: Line 36:
{{WH}}
{{WH}}
{{WS}}
{{WS}}
[[Category:Primary care]]
[[CME Category::Cardiology]]
 
[[Category:Angiology]]
[[Category:Angiology]]
[[Category:Cardiology]]
[[Category:Cardiology]]
[[Category:Disease]]
[[Category:Disease]]

Latest revision as of 20:31, 29 July 2020

https://https://www.youtube.com/watch?v=MjC1-odNY5k%7C350}}

Atherosclerosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Atherosclerosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Assessment of Cardiovascular Risk

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocadiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

ACC/AHA Guideline Recommendations

Assessment of cardiovascular risk

Secondary prevention

Case Studies

Case #1

Atherosclerosis overview On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Atherosclerosis overview

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Atherosclerosis overview

CDC on Atherosclerosis overview

Atherosclerosis overview in the news

Blogs on Atherosclerosis overview

Directions to Hospitals Treating Atherosclerosis

Risk calculators and risk factors for Atherosclerosis overview

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Atherosclerosis is a disease affecting arterial blood vessels. It is a chronic inflammatory response in the walls of arteries, in large part due to the deposition of lipoproteins (plasma proteins that carry cholesterol and triglycerides). It is commonly referred to as a "hardening" or "furring" of the arteries. It is caused by the formation of multiple plaques within the arteries.

Pathophysiology

Atherogenesis is the developmental process of atheromatous plaques. It is characterized by a remodeling of arteries involving the concomitant accumulation of fatty substances called plaques. One recent theory suggests that for unknown reasons, leukocytes such as monocytes or basophils begin to attack the endothelium of the artery lumen in cardiac muscle. The ensuing inflammation leads to formation of atheromatous plaques in the arterial tunica intima, a region of the vessel wall located between the endothelium and the tunica media and tunica adventitia. The bulk of these lesions are made of excess fat, collagen, and elastin. Initially, as the plaques grow only wall thickening occurs without any narrowing, stenosis of the artery opening, called the lumen; stenosis is a late event which may never occur and is often the result of repeated plaque rupture and healing responses, not the just atherosclerosis process by itself.

Diagnosis

History and Symptoms

According to United States data for the year 2004, for about 65% of men and 47% of women, the first symptom of atherosclerotic cardiovascular disease is heart attack or sudden cardiac death (death within one hour of onset of the symptom).

Laboratory Findings

Cardiac stress testing, traditionally the most commonly performed non-invasive testing method for blood flow limitations generally only detects lumen narrowing of ~75% or greater, although some physicians advocate that nuclear stress methods can detect as little as 50%.

Treatment

Medical Therapy

If atherosclerosis leads to symptoms, some symptoms such as angina pectoris can be treated. Non-pharmaceutical means are usually the first method of treatment, such as cessation of smoking and practicing regular exercise. If these methods do not work, medicines are usually the next step in treating cardiovascular diseases, and with improvements, have increasingly become the most effective method over the long term. However, medicines are criticized for their expense, patented control and occasional undesired effects.

Future or Investigational Therapies

Since about 2002, progress in understanding and developing techniques for modulating immune system function so as to significantly suppress the action of macrophages to drive atherosclerotic plaque progression are being developed with considerable success in reducing plaque development in both mice and rabbits. Plans for human trials, hoped for by about 2008, are in progress. Generally these techniques are termed immunomodulation of atherosclerosis.

References

Template:WH Template:WS CME Category::Cardiology